Irving, Texas–based Fluor Corp. announced April 10 that Grifols’ North Fractionation Facility in Clayton, N.C., was named the International Society for Pharmaceutical Engineering (ISPE) 2014 Facility of the Year for Project Execution. Fluor provided integrated engineering, procurement, construction management and front-end qualification for this 150,000-sq.-ft. plasma fractionation facility, which was built using modular construction techniques to meet an aggressive construction schedule, incorporate new centrifuge technology and expand existing plant utilities. Fluor-led projects have been chosen by ISPE for Facility of the Year awards three times over the past five years. Grifols completed its $4-billion takeover of RTP-based Talecris Biotherapeutics in June 2011.
“Fluor provides project management and execution excellence for pharmaceutical and biotech clients across the globe, and the Grifols blood plasma facility in North Carolina is a great example of successful outcomes,” said Juan G. Hernandez, president of Industrial Services for Fluor. “We provided Grifols with a single point of project accountability, continuity of intent and elimination of redundant project functions that resulted in a state-of-the-art facility.”
“Grifols has very high standards, and we can always rely upon the same high standards from Fluor in delivering our project execution needs,” said Detlef Kehm, Grifols vice president of engineering. “I am personally very pleased with ISPE’s independent validation of this superior project and with Fluor’s performance.”